Integer/linear mathematical programming models: a tool for allocating healthcare resources.

abstract：INTRODUCTION AND OBJECTIVE:The National Cholesterol Education Program recommends regular physician follow-up and lipid testing to promote adherence with lipid-lowering medications. The objective of this study was to determine whether lipid tests and physician visits after treatment initiation are indeed associated with...

journal_title：PharmacoEconomics

authors： Benner JS,Tierce JC,Ballantyne CM,Prasad C,Bullano MF,Willey VJ,Erbey J,Sugano DS

更新日期：2004-01-01 00:00:00

abstract：:The use of pharmacoeconomic tools has grown dramatically in the past decade as provision of healthcare throughout the industrialised world has required increased cost consciousness. However, pharmacoeconomic analysis has not yet been fully exploited as a conceptual underpinning for public or private health policy deci...

journal_title：PharmacoEconomics

authors： Greenberg PE,Arcelus A,Birnbaum HG,Cremieux PY,LeLorier J,Ouellette P,Slavin MB

更新日期：1999-11-01 00:00:00

abstract：:A number of recent findings from the literature imply that the value of a QALY varies depending on the concentration or dispersion of that QALY over treated individuals. Given that funding decisions are currently made under either the assumption of distributive-neutrality or some combination of explicit decision crite...

journal_title：PharmacoEconomics

authors： Mortimer D

更新日期：2006-01-01 00:00:00

abstract：:Recombinant human erythropoietin (rHuEpo) has been increasingly used in preterm infants in the last 3 to 4 years. Recent studies have indicated a reduction in blood transfusion requirements in infants receiving rHuEpo. No significant adverse effects have emerged, apart from iron deficiency (if iron supplementation is ...

journal_title：PharmacoEconomics

authors： Meyer MP

更新日期：1997-10-01 00:00:00

abstract：OBJECTIVES:This study provides the results of a cost-effectiveness analysis of levetiracetam as an adjunctive treatment for refractory epilepsy from the Canadian Ministry of Health perspective. The main objective is to estimate the expected cost-effectiveness ratio expressed as the incremental cost per seizure-free day...

journal_title：PharmacoEconomics

authors： Blais L,Sheehy O,St-Hilaire JM,Bernier G,Godfroid P,LeLorier JJ

更新日期：2005-01-01 00:00:00

abstract：OBJECTIVE:To estimate the economic value of pharmacological treatment of type 2 diabetes mellitus in overweight and obese patients using orlistat in addition to standard diabetes therapy (i.e., a sulphonlyurea, metformin or insulin) and weight management strategies as compared with standard diabetes therapy and weight ...

journal_title：PharmacoEconomics

authors： Maetzel A,Ruof J,Covington M,Wolf A

更新日期：2003-01-01 00:00:00

abstract：:The aim of this article was to perform a detailed methodological review of models used to estimate the cost effectiveness of drug treatment regimens for HIV infection in Europe and North America and assess the relationship between the different modeling approaches or key structural assumptions and the results. Electro...

journal_title：PharmacoEconomics

authors： Mauskopf J

更新日期：2013-11-01 00:00:00

abstract：:The past few years have seen rapid changes in the methods of decision-analytic modelling of healthcare programmes for the purposes of economic evaluation. This paper focuses on four developments in modelling that have emerged over the past few years or have become more widely used. First, no one optimal method for ext...

journal_title：PharmacoEconomics

authors： Weinstein MC

更新日期：2006-01-01 00:00:00

abstract：:The progressive increase in the prevalence of obesity and aging in the population is resulting in increased healthcare and disability spending. The burden of obesity is particularly relevant in old age, due to accumulating co-morbidities and changes in body composition. Sarcopenic obesity, a mix of over- and under-nut...

journal_title：PharmacoEconomics

authors： Corica F,Bianchi G,Corsonello A,Mazzella N,Lattanzio F,Marchesini G

更新日期：2015-07-01 00:00:00

abstract：:A survey of the prescribing of psychotropic drugs was carried out at the Psychiatric Hospital of Bahrain. This retrospective study on 60 inpatients of the Long Stay Ward revealed a man:woman ratio of 2.7. 91% of the men and 88% of the women were over 40 years old. 44 of the 60 patients had a diagnosis of schizophre...

journal_title：PharmacoEconomics

authors： El Hefny F,Al Haddad MK,Mathur V

更新日期：1992-03-01 00:00:00

abstract：:As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Sanofi Genzyme) of sarilumab (SAR; Kevzara®) to submit evidence of its clinical effectiveness and cost-effectiveness for previously treated moderate or severe rheumatoid arth...

journal_title：PharmacoEconomics

authors： Bermejo I,Ren S,Simpson E,Clowes M,Scott DL,Young A,Stevenson M

更新日期：2018-12-01 00:00:00

abstract：:An increasing number of ACE inhibitors have become available in recent years. Because these agents are all similar, careful scrutiny is required in order to determine specific advantages of particular agents when making formulary decisions. Differences between agents with regard to structure and tissue specificity hav...

journal_title：PharmacoEconomics

authors： Gerbrandt KR,Yedinak KC

更新日期：1996-12-01 00:00:00

abstract：OBJECTIVE:The objective of this article was to summarize the findings of all the available studies on alternative pharmacological treatments for asthma and assess their methodological quality, as well as to identify the main drivers of the cost effectiveness of pharmacological treatments for the disease. METHODS:A sys...

journal_title：PharmacoEconomics

authors： Rodriguez-Martinez CE,Sossa-Briceño MP,Castro-Rodriguez JA

更新日期：2018-10-01 00:00:00

abstract：:The application of cost-effectiveness methodology is particularly important in widespread diseases such as hypertension. However, because prospective cost-effectiveness analyses comparing different antihypertensive drugs are not currently available, differences in the cost effectiveness of these drugs can only be esti...

journal_title：PharmacoEconomics

authors： Van Bortel LM,Ament AJ

更新日期：1995-12-01 00:00:00

abstract：:We have defined the effect and acceptability of a locally developed general practice programme for the modification of prescribing. This voluntary programme consisted of prescription analysis and feedback, followed by visits from a pharmacist, a therapeutic bulletin on benzodiazepine prescribing, and use of a locally ...

journal_title：PharmacoEconomics

authors： Ferguson RI,Salmond CE,Maling TJ

更新日期：1995-06-01 00:00:00

abstract：BACKGROUND:Currently, the most popular hospital payment method in China is fee-for-service (FFS) with a global budget cap. As of December 2009, a policy change means that heart stents are covered by public health insurance, whereas previously they were not. This policy change provides us an opportunity to study how a c...

journal_title：PharmacoEconomics

authors： Yuan S,Liu Y,Li N,Zhang Y,Zhang Z,Tao J,Shi L,Quan H,Lu M,Ma J

更新日期：2014-03-01 00:00:00

abstract：BACKGROUND:In the Netherlands, decisions about the reimbursement of new pharmaceuticals are based on cost effectiveness, as well as therapeutic value and budget impact. Since 1 January 2005, drug manufacturers are formally required to substantiate the cost effectiveness of drugs that have therapeutic added value in com...

journal_title：PharmacoEconomics

authors： Hoomans T,Severens JL,van der Roer N,Delwel GO

更新日期：2012-03-01 00:00:00

abstract：:Using the method of willingness to pay (WTP), this study assesses the value of a new antidepressant, moclobemide, relative to that of tricyclic antidepressants (TCAs), which have equivalent efficacy but less favourable adverse effect profiles. From a published meta-analysis of controlled clinical trials, we identified...

journal_title：PharmacoEconomics

authors： O'Brien BJ,Novosel S,Torrance G,Streiner D

更新日期：1995-07-01 00:00:00

abstract：:Randomized controlled trials provide unbiased estimates of treatment effect through reducing the attribution of observed differences in outcome to the play of chance or the treatment of interest. Issues in the design of randomized trials may lead to a dilution or magnification of treatment effect when compared with cl...

journal_title：PharmacoEconomics

authors： Freemantle N,Hessel F

更新日期：2009-01-01 00:00:00

abstract：:Migraine headache is responsible for significantly more healthcare resource and lost labour costs than previously reported. Costs associated with migraine were assessed via a survey conducted in 940 patients, 70% of whom responded. All met the International Headache Society's diagnostic criteria for migraine and had ...

journal_title：PharmacoEconomics

authors： Osterhaus JT,Gutterman DL,Plachetka JR

更新日期：1992-07-01 00:00:00

abstract：:Appropriate discounting rules in economic evaluations have received considerable attention in the literature and in national guidelines for economic evaluations. Rightfully so, as discounting can be quite influential on the outcomes of economic evaluations. The most prominent controversies regarding discounting involv...

journal_title：PharmacoEconomics

authors： Attema AE,Brouwer WBF,Claxton K

更新日期：2018-07-01 00:00:00

abstract：:Given the policy relevance and growing volume of research measuring individuals' willingness to pay (WTP) for health-related goods and services, meta-analysis provides a potentially rich set of tools for answering key questions about this research area. In particular, when taken as a whole, what does the existing empi...

journal_title：PharmacoEconomics

authors： Van Houtven G

更新日期：2008-01-01 00:00:00

abstract：:Health economic models for identifying therapeutic options that maximise health benefits from limited healthcare resources are being developed in a number of therapeutic areas. The development of such a model for upper gastrointestinal (UGI) symptoms to support decision-making by primary care clinicians is of particul...

journal_title：PharmacoEconomics

authors： Haycox A,Butterworth M,Walley T,Barton S

更新日期：1998-01-01 00:00:00

abstract：OBJECTIVE:Patients with cancer-associated neutropenia are at high risk of developing severe infections which can be fatal if treatment is not promptly administered. For this reason, fever is treated as soon as possible with broad spectrum antibacterial therapy. The objective of this study was to conduct a cost analysis...

journal_title：PharmacoEconomics

authors： Bucaneve G,Menichetti F,Del Favero A

更新日期：1999-01-01 00:00:00

abstract：BACKGROUND:Interventions in health care often not only have an effect on patients, but also on their informal caregivers. Caregiving can have a profound impact on the health and wellbeing of carers. Ignoring these spillovers in economic evaluations risks labelling interventions mistakenly as cost-effective, at the expe...

journal_title：PharmacoEconomics

authors： Hoefman RJ,van Exel J,Brouwer WBF

更新日期：2019-04-01 00:00:00

abstract：:Answering the demanding questions asked of pharmacotherapy in the 21st century will require more reliance on the disciplines of pharmacoepidemiology and pharmacoeconomics. Pharmacoepidemiology can help assess patterns and appropriateness of drug utilisation, provide explanations for poor compliance, quantify the frequ...

journal_title：PharmacoEconomics

authors： Avorn J

更新日期：2004-01-01 00:00:00

abstract：:We review regulation of two important parameters for third-party payers and manufacturers of prescription drugs: regulation of reimbursement and pricing. We find that centralised regulation of reimbursement and pricing prevails in the 15 original EU member countries (EU-15) and in European Free Trade Association (EFTA...

journal_title：PharmacoEconomics

authors： Gress S,Niebuhr D,May U,Wasem J

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Head and neck cancer (HNC) and its treatment can affect communication, nutrition, and physical appearance, and the global impact of this disease on patients' quality of life may be substantial. OBJECTIVE:The aim of this systematic literature review was to describe the impact of HNC and its treatment on the ...

journal_title：PharmacoEconomics

authors： Wissinger E,Griebsch I,Lungershausen J,Byrnes M,Travers K,Pashos CL

更新日期：2014-12-01 00:00:00

abstract：:Published estimates for the treatment costs of breast cancer vary widely in methodology, perspective, patient populations and time horizon. We systematically summarized and analysed the published literature on per-patient costs of breast cancer, and highlight the perspectives, populations studied, time horizons and fu...

journal_title：PharmacoEconomics

authors： Campbell JD,Ramsey SD

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Pharmaceuticals are usually granted a marketing authorisation on the basis of randomised controlled trials (RCTs). Occasionally the efficacy of a treatment is assessed without a randomised comparator group (either active or placebo). OBJECTIVE:To identify and develop a taxonomic account of economic modellin...

journal_title：PharmacoEconomics

authors： Hatswell AJ,Freemantle N,Baio G

更新日期：2017-02-01 00:00:00